. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Leukemia. 2021 Mar 2;35(9):2539–2551. doi: 10.1038/s41375-021-01179-4

Table 1.

Pretreatment characteristics for the 441 CRind patients and all 717 randomized patients

	All Induction CRs (CRind) (N=441)		All 717 randomized patients
	Midostaurin (N=234)	Placebo (N=207)	All 717 randomized patients
Age in years, median (range)	47.8 (20–60)	49.9 (18–60)	48 (18–61)
Female, N (%)	114 (49%)	120 (58%)	398 (56%)
Randomization strata: FLT3 mutation, N (%)
TKD (No ITD)	56 (24%)	48 (23%)	162 (23%)
ITD (ratio <0.7)	116 (50%)	93 (45%)	341 (48%)
ITD (ratio ≥0.7)	62 (27%)	66 (32%)	214 (30%)
ELN 2017 Groups (see text)
Favorable	77 (50%)	66 (51%)	197 (45%)
Intermediate	37 (24%)	39 (30%)	123 (28%)
Adverse	40 (26%)	23 (18%)	121 (27%)
Pre-treatment WBC, median x10³/ul (range)	35 (0.6–421.8)	31.3 (0.8–308.8)	34.9 (0.6–421.8)

ELN denotes European LeukemiaNet; WBC, white blood cell count.

CRind patients achieved a CR at any time during their induction period, prior to starting consolidation.